ACUTE TOXICITY PROFILE OF CONCURRENT CHEMORADIATION IN CARCINOMA CERVIX WITH THE INTEGRATION OF BRACHYTHERAPY DURING EXTERNAL BEAM RADIATION THERAPY
Author:
Kandipalli Shilpa1, Santhosh Vandanasetti2
Affiliation:
1. Assistant Professor of Medical Oncology, Andhra Medical College/KGH, Visakhapatnam. 2. Consultant Medical Oncologist, Kailash Cancer Hospital and Research Centre, Vadodara.
Abstract
Background: Concurrent chemoradiation with weekly cisplatin is the treatment of choice in a case of
carcinoma cervix. Prolonging treatment time is detrimental to disease control. When brachytherapy is
scheduled during external beam radiation therapy (EBRT), treatment time can be shortened signicantly thereby improving
local control. As the delivery of radiation with brachytherapy is uniform and spares normal tissues it reduces the acute
toxicities. In this study, we aimed to study the acute toxicities associated with this unique scheduling of brachytherapy along
with EBRT. Fifty patients with carcinoma cervix between stage IIA to IIIB treated at our institution with chemo-Methods:
radiation were included in the study. Concurrent chemotherapy was delivered using weekly cisplatin (40mg/m2) for 5 cycles.
EBRT was delivered using four eld box technique. HDR brachytherapy was introduced after 3rd week of EBRT. Brachytherapy
was delivered in 3 fractions each 8.5Gy at the end of the 3rd, 4th, and 5th week. Acute RTOG toxicities were assessed during the
treatment and one week post treatment. The median age of the study population is 45 years. Eighty four percent ofResults:
patients received 4 or more cycles of concurrent chemotherapy, whereas 16% of patients received only 3 cycles of concurrent
chemotherapy. Most common toxicity observed in the current study population is diarrhea followed by vomiting. Most toxicities
are of RTOG grade 0 or 1 and none of the patients developed grade 4 toxicity. Only two patients developed grade 3 diarrhea
and one patient developed grade 3 neutropenia. Integrating brachytherapy schedule along with EBRT decreasesConclusion:
overall treatment time with an acceptable acute toxicity prole.
Publisher
World Wide Journals
Reference9 articles.
1. 356-india-fact-sheets.pdf. (n.d.). Retrieved April 11, 2022, from https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf 2. Chapter8CancerCervixUteri.pdf. (n.d.). Retrieved April 11, 2022, from https://ncdirindia.org/All_Reports/Report_2020/resources/Chapter8CancerCervixUteri.pdf 3. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., Walker, J. L., & Gersell, D. (1999). Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. The New England Journal of Medicine, 340(15), 1154–1161. https://doi.org/10.1056/NEJM199904153401503 4. Pearcey, R., Brundage, M., Drouin, P., Jeffrey, J., Johnston, D., Lukka, H., MacLean, G., Souhami, L., Stuart, G., & Tu, D. (2002). Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20(4), 966–972. 5. Perez, C. A., Grigsby, P. W., Castro-Vita, H., & Lockett, M. A. (1995). Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 32(5), 1275–1288. https://doi.org/10.1016/0360-3016(95)00220-S
|
|